The newly approved vaccine targets multiple circulating variants, promising enhanced protection and availability across ...

It's the second straight year that rivals Moderna and Pfizer have gotten a head start in the race to roll out fall vaccines. Novavax Inc. is once again lagging behind rivals Pfizer Inc. and ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

1, said CEO John Jacobs. Earlier this month ... 2 strain for 2024-25 COVID-19 vaccines. Novavax's traditional protein-based shot offers an alternative vaccine technology to those that are based ...

Novavax’s updated vaccine includes a monovalent component against the Omicron variant JN.1 strain of SARS-CoV-2. The company’s CEO John C Jacobs said: “Our updated vaccine targets JN.

The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's COVID shot. The updated vaccine is authorized for use in individuals 12 years of ...

1, said CEO John Jacobs. JN.1 was the dominant strain ... 2 strain for 2024-25 COVID-19 vaccines. Novavax's traditional protein-based shot offers an alternative vaccine technology to those that ...

1 lineage viruses," Novavax CEO John Jacobs said in a statement. Novavax said it expects its shot to be "broadly available" in thousands of locations across the U.S., including retail and ...